Mononuclear/JJ
leukocyte/NN
glucocorticoid/NN
receptor/NN
binding/NN
characteristics/NNS
and/CC
down-regulation/NN
in/IN
major/JJ
depression/NN
./.

Some/DT
patients/NNS
with/IN
major/JJ
depressive/JJ
disorder/NN
(/(
MDD/NN
)/)
have/VBP
elevated/JJ
plasma/NN
cortisol/NN
concentrations/NNS
and/CC
show/VBP
failure/NN
to/TO
suppress/VB
cortisol/NN
secretion/NN
upon/IN
administration/NN
of/IN
dexamethasone/NN
(/(
DEX/NN
)/)
,/,
yet/CC
they/PRP
do/VBP
not/RB
have/VB
Cushingoid/JJ
features/NNS
./.
=====
To/TO
study/VB
whether/IN
this/DT
represents/VBZ
glucocorticoid/NN
(/(
GC/NN
)/)
resistance/NN
,/,
[3H]-DEX-binding/JJ
assays/NNS
were/VBD
used/VBN
to/TO
measure/VB
,/,
in/FW
vitro/FW
,/,
the/DT
GC/NN
receptor/NN
affinity/NN
(/(
1/Kd/NN
)/)
and/CC
number/NN
(/(
Bmax/NN
)/)
in/IN
mononuclear/JJ
leukocytes/NNS
of/IN
11/CD
MDD/NN
patients/NNS
and/CC
15/CD
control/JJ
subjects/NNS
./.
=====
No/DT
receptor/NN
abnormalities/NNS
were/VBD
detected/VBN
in/IN
the/DT
MDD/NN
group/NN
;/:
thus/RB
any/DT
cellular/JJ
defect/NN
leading/VBG
to/TO
a/DT
lack/NN
of/IN
responsiveness/NN
to/TO
GC/NN
in/IN
the/DT
MDD/NN
patients/NNS
,/,
if/IN
present/JJ
,/,
probably/RB
lies/VBZ
beyond/IN
the/DT
initial/JJ
receptor/NN
binding/NN
./.
=====
DEX/NN
(/(
1.0/CD
mg/NN
orally/RB
)/)
was/VBD
administered/VBN
to/TO
study/VB
in/FW
vivo/FW
GC/NN
receptor/NN
down-regulation/NN
./.
=====
Compared/VBN
to/TO
the/DT
control/JJ
group/NN
,/,
fewer/JJR
depressed/JJ
subjects/NNS
down-regulated/VBD
Bmax/NN
after/IN
DEX/NN
./.
=====
By/IN
paired/JJ
t-test/NN
,/,
Bmax/NN
decreased/VBD
significantly/RB
in/IN
the/DT
control/JJ
group/NN
but/CC
not/RB
in/IN
the/DT
depressed/JJ
group/NN
./.
=====
Receptor/NN
number/NN
on/IN
the/DT
control/JJ
day/NN
did/VBD
not/RB
correlate/VB
significantly/RB
with/IN
the/DT
degree/NN
of/IN
receptor/NN
down-regulation/NN
,/,
severity/NN
of/IN
depression/NN
or/CC
cortisol/NN
concentrations/NNS
across/IN
all/PDT
the/DT
subjects/NNS
./.
=====
These/DT
results/NNS
do/VBP
not/RB
lend/VB
support/NN
to/TO
previous/JJ
reports/NNS
suggesting/VBG
that/IN
GC/NN
resistance/NN
in/IN
MDD/NN
results/VBZ
from/IN
a/DT
GC/NN
receptor-binding/JJ
abnormality/NN
,/,
and/CC
they/PRP
emphasize/VBP
the/DT
importance/NN
of/IN
considering/VBG
receptor/NN
studies/NNS
in/IN
the/DT
context/NN
of/IN
GC-mediated/JJ
cell/NN
processes/NNS
in/IN
order/NN
to/TO
identify/VB
the/DT
exact/JJ
cellular/JJ
defect/NN
(/(
s/NNS
)/)
leading/VBG
to/TO
GC/NN
resistance/NN
./.